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Análisis en silico del compuesto de formononetina como un anticáncer de mama
A
b
st
ra
ct
R
es
u
m
en
or long the relationship between estrogen and 
cancer has been proved. Formononetin is a 
phytoestrogen which has been reported to have an-
ticancer effects. Phytoestrogens have the same structure 
and properties as human estrogen and can interact with 
ER-α without inducing any cell proliferation. While anti-
cancer properties of Formononetin in prevention of oth-
er cancers like prostate and carcinoma colon have been 
studied, its effects on breast cancer remain unknown. The 
aim of the present study is to analyse the formononetin 
compound as a competitor of estrogen in terms of the 
bond quality with ER-α. The method used in this study 
was in silico or computation by molecular docking meth-
od using PvRx software. The data was also analysed us-
ing Discovery Studio software. The results showed that 
the formononetin compounds have a value of free energy 
equal to -7.3 kcal/mol, lower than 17-β-Estradiol (natural 
estrogen) that is -6.4 kcal/mol, but higher than 3 alkyl-
naphthalene (estrogen synthetic) that is -11.2 kcal/mol. 
Based on the results, formononetin has a great potential 
as an estrogen competitor because it has a value of free 
energy that is lower than the natural estrogen.
Keywords: Breast cancer; estrogen; formononetin; in 
silico modeling
urante mucho tiempo se ha comprobado 
la relación entre estrógeno y cáncer. La 
formononetina es un fitoestrógeno que 
se ha informado que tiene efectos anticancerígenos. Los 
fitoestrógenos tienen la misma estructura y propiedades 
que el estrógeno humano y pueden interactuar con ER-α 
sin inducir ninguna proliferación celular. Si bien se han es-
tudiado las propiedades anticancerígenas de Formonone-
tin en la prevención de otros cánceres como la próstata 
y el carcinoma de colon, sus efectos sobre el cáncer de 
mama siguen siendo desconocidos. El objetivo del pre-
sente estudio es analizar el compuesto de formononetina 
como un competidor del estrógeno en términos de la cali-
dad del enlace con ER-α. El método utilizado en este es-
tudio fue in silico o computación mediante el método de 
acoplamiento molecular utilizando el software PvRx. Los 
datos también se analizaron utilizando el software Discov-
ery Studio. Los resultados mostraron que los compuestos 
de formononetina tienen un valor de energía libre igual a 
-7.3 kcal/mol, menor que 17-β-estradiol (estrógeno natu-
ral) que es -6.4 kcal/mol, pero mayor que 3 alquilnaftale-
no (sintético de estrógeno) Eso es -11.2 kcal/mol. Basado 
en los resultados, formononetin tiene un gran potencial 
como competidor de estrógeno porque tiene un valor de 
energía libre que es más bajo que el estrógeno natural.
Palabras clave: cáncer de mama; estrógeno; for-
mononetina; modelado in silico
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ancer is a disease characterized by abnor-
mal cell growth in body tissues with mu-
tations and changes in the biochemical 
structure1. Breast cancer is a type of cancer that is often 
encountered in women, world-wide, representing 16% of 
all types of cancer suffered by women. 519,000 deaths 
were reported due to breast cancer2. Breast cancer be-
gins with abnormal cell division of breast tissue that is 
capable of invading and distributing in other organs3.
Breast cancer can be caused by other factors such as es-
trogen and estrogen receptors. Estrogen is a hormone 
that is very closely related to female reproduction. How-
ever, high levels of endogenous estrogen as well as hor-
monal therapy with estrogen for menopause are linked to 
higher risk of breast cancer4. Estrogen is able to stimulate 
the proliferation of epithelial cells in the breast gland by 
increasing estrogen receptor which mediates transcription 
of genes. Increased estrogen in the female body will re-
sult in hyperproliferation, and thus can potentially cause 
breast cancer5.  
Phytoestrogens are largely distributed in plants and have 
similar structures and functions with human estrogen; 
therefore, they have the capability to bind to estrogen 
receptors6. There are three main classes of phytoestro-
gens namely isoflavones (which mostly can be found in 
soybeans and soy products); lignans (which widely can 
be found in seeds, whole grains, berries, fruit, vegeta-
bles, and nuts); and coumestans (which are distributed 
in broccoli and sprouts). Phytoestrogens bind weakly to 
estrogen receptors, yet they do not cause cell proliferation 
reactions. Although the role of phytoestrogens in human 
body is ambiguous, they are reported7 to be protective 
against breast cancer owing to their structure (Potential, 
see conclusion). Therefore, phytoestrogens are one of the 
potential compounds that act as estrogen competitors in 
the body to reduce cell proliferation. One of the potential 
phytoestrogens is formononetin. Formononetin is an iso-
flavone and can be found in several types of plants such 
as soybeans, katuk leaves, and red clover. Figure 1 shows 
is the structure of formononetin:
Formononetin as an effective anticancer prevents prostate 
cancer and carcinoma colon9, but its role in breast cancer 
is unknown.
The most common treatment methods for breast cancer 
are surgery, chemotherapy, hormonal therapy, and immu-
nologic therapy. However, they have many disadvantages. 
For instance, although chemotherapy kills cancer cells, it 
also negatively affects normal cells with rapid proliferation 
rates, such as hair follicles, bone marrow and digestive tract 
cells, resulting in typical chemotherapy side effects such as 
hair and skin loss or skin dry up1. Therefore, researchers are 
looking for more effective treatments with minimum side 
effects. In line with this, one approach is exploring antican-
cer compounds like phytoestrogens from natural sources. 
This study aims to determine bonds between formonone-
tin and estrogen receptor alpha (ER-α) and to examine the 
potential of formononetin as an estrogen competitor in 
the human body using the in silico method. 
In silico is a term used to refer to computational research 
work. This method is often used to find new drugs by pre-
dicting the interaction between the candidate drug com-
pounds (ligand) and the target receptor. There are many 
computational methods that can be used and one of 
them is molecular docking10.  Molecular docking helps to 
predict the natural process which occurs within seconds 
in a cell11. It is a computational procedure used to predict 
conformation of proteins or molecules of nucleic acids 
(DNA or RNA), and ligands. The process involves placing 
molecules in appropriate configurations to interact with 
a receptor. The molecular docking algorithms execute 
quantitative predictions of binding energetics, and pro-
vide rankings of docked compounds based on the binding 
affinity of ligand-receptor complexes11. 
Research Design
This study was an experimental research using the in silico 
approach. The instrument used in this research were the 
PyRx and BIOVIA Discovery Studio 2017 R2 softwares. The 
materials used in the experiment were the three-dimen-
sional structure of formononetin in mol2 form, estrogen 
receptors alpha (natural estrogen) and three-dimensional 
3-alkyl naphthalene (synthetic estrogen). Formonone-
tin was obtained from zinc.docking.org under the code 
ZINC18847036, the estrogen receptors alpha were down-
loaded from http: //www.rcsb.org/pdb/home/home.do 
using 3DT3 code in the .pdb format and 3-alkyl naph-
thalene can be downloaded at pdb.org using 3DT3 code.
The in silico method employed in this study includes mo-
lecular docking of proteins and ligands to predict ligand 
binding model in the dominant area known as protein in a 
three-dimensional structure12. This research is carried out 
computationally, consisting of the following steps:
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Figure 1. Structure of formononetin8
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Preparation of test compound
In this study three compounds consisting of three ligands 
and one receptor were tested. The three ligands consisted 
of one test ligand namely formononetin and two control 
ligands namely 17-β-estradiol (natural estrogen) and 3-al-
kyl naphthalene (synthetic estrogen). The receptor used 
are estrogen receptors alpha (ER-α). All ligands should be 
saved in the mol2 format that is suitable for PyRx soft-
ware. The ER α should be separated by their innate ligand, 
so that they will not overlap with the test ligands when 
molecular docking is carried out.
Molecular Docking Process
Molecular docking is a process of uniting or combining 
of test compounds with their receptors. The combina-
tion process was carried out using the PvRx software. 
The outcome from this process which was the informa-
tion on the conformation and binding affinity value (free 
energy) of the ligands would be further analysed using 
BIOVIA Discovery Studio 2017 R2 software13. Conforma-
tion is a three-dimensional image of interactions between 
test ligands and ER-α which results from molecular dock-
ing processes.  Based on the result of conformation, the 
number and type of bond formed between the test ligand 
and ER-α will also be identified. The binding affinity value 
i.e. free energy values, show the bond calculation formed 
between the test ligand and the receptor.  
Analysis Molecular Docking Results
The conformation and binding value of free energy ob-
tained from molecular docking process were then visu-
alized using BIOVIA Discovery Studio 2017 R2 software. 
The value of binding affinity is always negative because 
it describes the initiation between ligands and receptors. 
Low value of binding affinity would indicate a good bond 
quality. In this process also, the location of the tested li-
gands in the alpha ER-α was identified. In addition, the 
number and type of bond formed between the test ligand 
and ER-α will also be scrutinised. 
stimation of the binding mode of a ligand in-
side the binding site of a protein of known 
structure is very important in rational drug 
design. Molecular docking simulations on the crystal 
structure of estrogen receptor were employed in order to 
study in silico the ability of the studied test ligands to bind 
to the said receptor.
The findings of the analysis have shown that all the three 
tested ligands indicate positions that are similar to the ER-α 
(estrogen receptors alpha). Based on Figure 2 formonone-
tin (blue), 3-alkyl naphthalene (red) and 17-β-estradiol 
(green) are on the active site of the ER-α. This indicates 
that all three test ligands are in the correct position on 
the receptor. 
Table 1 below illustrates the number of interacted bonds 
and the types of bonds between the tested ligands and 
ER-α.
 Table 1. Comparison of number of interaction bonds
No Name of Ligand
Bond
Hydrogen 
Bond
Hydrophobic 
Bonds
Other 
Bond
1 Formononetin - 8 -
2 3-alkyl naphthalene 3 14 -
3 17-β-estradiol - 5 1
Based on Table 1, the interaction formed between for-
mononetin and ER-α is a hydrophobic bond and consists 
of 8 bonds, while the interaction between 3-alkyl naph-
thalene and ER-α forms 3 hydrogen bonds and 14 hydro-
phobic bonds. The interaction between 17-β-estradiol 
and ER-α forms 5 hydrophobic bonds and 1 other bond. 
Figures 3, 4, and 5 below provide a further information 
regarding the bonds that have been formed. ER-α is a pro-
tein that composed by amino acids. Figures 3, 4, and 5 
show the amino acids from ER-α which are bound to each 
test ligand. The number of amino acids bound to the test 
ligand illustrates the number of bonds formed between 
the test ligand and ER-α.
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Figure 2. Comparison of conformations of third ligands 
(formononetin, 3-alkyl naphthalene, and 17-β-estradiol).
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Figure 3 shows the bond between formononetin com-
pounds and the residue (amino acid of receptor). There 
are 6 residues in the ER-α compound (in red) consisting 
of LEU384 (Leucine 384), LEU525 (Leusin 525), PHE404 
(Phenylalanine 404), ALA350 (Alanine 350), LEU387 (Le-
usin 387) and MET388 (Methionine 388). The numbers 
that follow the name of amino acid is the sequential num-
bers in the ER-α structure. 
Figure 4 shows the bond between 3-alkyl naphthalene 
compounds and the residues (amino acid of receptor). 
There are 12 residues that are bound to ER-α including 
GLU353 (Glutamic Acid 353), GLY521 (Glycine), PHE404 
(Phenylalanine), LEU346 (Leucine), MET388 (Methio-
nine 388), LEU391 (Leucine 391), LEU428 (Leucine 428), 
ILE424 (Isoleucine 424), LEU525 (Leusin 525), ALA350 
(Alanin 350), LEU349 (Leusin 349), LEU387 (Leusin 387).
Figure 5 shows the bond between 17-β-estradiol com-
pounds and the residues (amino acid of receptor). There 
are 5 residues in this compound is 5 that are bound to 
ER-α including TRP383 (Tryptophan 383), LEU525 (Leu-
cine 525), TYR526 (Tyrosine 526), LYS529 (Lysine 529), 
and MET528 (Methionine 528). 
Calculation of Affinity Binding: The affinity binding values 
indicate the quality of affinity (bond strength) between 
the tested ligands and ER-α. Table 2 below illustrate the 
values obtained from the analysis.
Table 2. The affinity binding value (kcal / mol) of for-
mononetin, 3-alkyl naphthalene and 17-β-estradiol with 
estrogen receptor alpha
Table 2. The affinity binding value (kcal / mol) of 
formononetin, 3-alkyl naphthalene and 17-β-estradiol with 
estrogen receptor alpha
No Name of Ligand Binding Affinity (kcal/mol)
1 3-alkyl naphthalene -11.2
2 Formononetin -7.1
3 17-β-estradiol -6.4
The bond strength between the ligand and its receptors 
is predicted by the value of binding affinity obtained from 
the docking results. The value of binding affinity is the 
power of interaction between two molecules or more. 
The greater the value of binding affinity is, the lower the 
bond  between the receptor and the ligand will be14.
Based on Table 2, the formononetin compound shows low-
er free energy (-7.1 kcal/mol) compared to 17-β-estradiol 
(-6.4), but higher when compared to 3-alkyl naphthalene 
(-11.2). This seems to suggest that formononetin has the 
potential to become the competitor of estrogen in the 
body, because the estrogen in the body is 17-β-estradiol. 
According to the literature14, the bonding of a compound 
can be considered to be good or strong if the value of 
binding affinity is lower because if the binding affinity is 
low then the bond formed is more stable, when com-
pared with the high binding affinity value. Therefore, the 
higher value of binding affinity will result in less stable 
interaction between the bonds.
he compound of formononetin is a phytoestro-
gen compound capable of binding to estrogen 
receptor alpha (ER-α), with free energy value of 
-7.1 kcal/mol, lower than the control compound of -6.4 
kcal / mol. However, formononetin is no better than that 
of other 3- alkyl naphthalene control compounds with free 
energy values of -11.2 kcal / mol. Based on the results, the 
compounds of formononetin has the potential to be an 
active ligand with the estrogen alpha receptor (ER-α). For 
Figure 3. Visualization of formononetin interactions 
(green) with estrogen receptor alpha (red).
Figure 4. Visualization of 3-alkyl naphthalene  interac-
tions (blue)  with estrogen receptor alpha (red).
Figure 5. Visualization of 17-β-estradiol interactions 
(red)  with estrogen receptor alpha (blue).
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future studies, more tests on formononetin compounds 
using the in vivo and in vitro methods can be conducted 
to test the stability of interaction between formononetin 
and the estrogen alpha receptor (ER-α) through molecular 
dynamic tests.
Based on the molecular docking results, the formononetin 
compounds have a better bonding quality to alpha estro-
gen receptors than the natural estrogens (17-β estradiol), 
but no better when compared with naphthalene. This in-
dicates that formononetin has the potential as a natural 
estrogen competitor and therefore, it could be a candi-
date to be used as breast anti cancer drug. 
Rational drug design of phytoestrogen derivatives unlocks 
new outlooks to selectively utilize the health beneficial 
properties of this natural compound for the treatment of 
breast cancer. The results of present study can be used as 
a reference for future studies on alternative treatments for 
breast cancer. Our findings have shown that formomon-
etin has the capability of prevention and/or treatment of 
cancer. The use of formononetin as an alternative treat-
ment in breast cancer may reduce the high rate of mortal-
ity in breast cancer patients.
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